在高身体活动的阿尔茨海默氏症中,突触连接和突触传播的改变
Can Wu1, Tingting Ruan1, Yalan Yuan1
1Department of Physiology and Pathophysiology, Health Science Center, Ningbo University, Ningbo, Zhejiang, China.
Journal of Alzheimer's disease : JAD
|May 17, 2024
概括
高度体力活动 (HPA) 可能通过增强突触功能来逆转阿尔茨海默病 (AD) 病理. 这项研究揭示了HPA对参与突触囊泡运输的关键蛋白质进行上调,这对神经元通信至关重要.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 身体活动代表了一种有希望的生活方式干预,可以减缓AD的进展.
研究的目的:
- 为了研究AD病理的基础分子机制.
- 确定身体活动如何影响这些机制.
主要方法:
- 对阿兹海默症患者和身体活跃的老年人的综合转录基因分析.
- 在独立数据集和小鼠模型中验证 (APP/PS1转基因小鼠).
- 定量聚合酶连锁反应 (qPCR) 用于枢纽基因表达分析.
主要成果:
- 确定了195个差异表达基因 (DEGs),在AD与高身体活动 (HPA) 中具有相反的调节.
- 参与突触囊泡循环和传播的关键DEG在AD下调,在HPA上调.
- 在小鼠模型中,四个关键的突触囊泡周转基因 (SYT1,SYT4,SH3GL2,AP2M1) 被确定,它们的表达被HPA逆转.
结论:
- 高度的体力活动可以通过调节突触囊泡运输蛋白来抵消AD病理.
- 增强突触囊泡的循环和神经元间的通信是AD的身体活动的潜在好处.
- 这项研究为身体活动对抗阿尔茨海默病的保护机制提供了新的见解.
相关概念视频
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Role of Neurotransmitters in Memory
531
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
531
Long-term Potentiation
2.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120


